Defunct Company
Total Trials
5
As Lead Sponsor
3
As Collaborator
2
Total Enrollment
399
NCT00621270
Safety and Effectiveness Study of BCI-540 Versus Placebo in the Treatment of Major Depressive Disorder With Concomitant Anxiety
Phase: Phase 2
Role: Lead Sponsor
Start: Jan 31, 2008
Completion: Oct 31, 2009
NCT00705003
Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD)
Role: Collaborator
Start: May 31, 2008
Completion: Dec 31, 2008
NCT00731653
Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD)
Start: Jul 31, 2008
Completion: Jan 31, 2009
NCT01546051
A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers
Phase: Phase 1
Start: Oct 31, 2011
Completion: Feb 29, 2012
NCT01548703
A Multiple Ascending Dose Study of BCI-838 in Healthy Volunteers
Start: Feb 29, 2012
Completion: Apr 30, 2012